New York, United States – Sep 10, 2026 – Ace Therapeutics, a leading CRO service provider for ophthalmic drug research and development, has rolled out full‑scope customized ocular drug delivery services to help biotech and pharmaceutical partners address ocular barriers that limit drug delivery to target tissues and boost therapeutic outcomes for ocular disease candidates.

Ocular drug development faces substantial biological hurdles. Multiple anatomical and physiological barriers, including the tear film, corneal epithelium, conjunctiva, and blood-ocular barriers, can limit drug retention, penetration, and distribution to target ocular tissues. For topical ophthalmic delivery, strategies that prolong precorneal residence and improve corneal or conjunctival penetration can help enhance ocular exposure. Among these approaches, sustained-release ophthalmic formulations can prolong drug release, reduce dosing frequency, and potentially improve local drug exposure while limiting unnecessary systemic exposure.

Leveraging its proprietary ocular drug delivery platform, Ace Therapeutics supports the development of diverse controlled/sustained-release ophthalmic formulations and multiple advanced delivery modalities. Its technical portfolio covers solid lipid nanoparticles, liposomes, dendrimers, hydrogel systems, microneedles, ocular implants, and ocular inserts, for both anterior‑segment and posterior‑segment eye disorders.

The customized ocular drug delivery services span the full early‑development workflow: pre‑formulation assessment, formulation feasibility evaluation, formulation development, identification and standardization of testing methods, experimental‑design‑driven process optimization, as well as sterile filtration assessment. Systems built through these services feature sustained drug release, enhanced ocular‑tissue penetration, accurate dosing, and simplified administration. Backed by complete pharmaceutical expertise and sophisticated laboratory equipment, Ace Therapeutics supports ocular drug delivery development programs for clients worldwide.

“A core challenge for modern ophthalmic research lies in delivering therapeutically‑relevant drug concentrations to target ocular compartments with minimal off‑target side effects,” said the marketing manager at Ace Therapeutics. “Our company combines standardized workflows with project‑tailored development schemes, aiming to move candidate ophthalmic delivery technologies toward key development milestones.”

Beyond formulation work, Ace Therapeutics also offers complementary supporting resources such as ocular pharmacology, pharmacokinetics, histopathology, and preclinical ophthalmic imaging services to support end‑to‑end program advancement. Biopharma partners and academic groups interested in these capabilities may reach Ace Therapeutics for further technical details and project consultation.

About Ace Therapeutics

Ace Therapeutics is a leading preclinical contract research organization (CRO) based in New York, providing customized disease models, drug development support, and preclinical research services across multiple therapeutic areas, including ophthalmology. Ace Therapeutics provides integrated preclinical solutions including efficacy testing, pharmacokinetic analysis, toxicology studies, and biomarker development for pharmaceutical companies, academic institutions, and research organizations worldwide.

Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email: Send Email
Phone: 1 516 441 0167
Country: United States
Website: https://www.acetherapeutics.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ace Therapeutics Expands Customized Ocular Drug Delivery Services to Support Ophthalmic Drug Development

Media gallery

About The Author
Ace Therapeutics